Evidence map›Paper›PMID 28610792›Full record

ArticleTuberculosis (Edinburgh, Scotland)2017

Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection.

Andrew Chancellor, Andrew White, Anna S Tocheva, Joe R Fenn, Mike Dennis, Liku Tezera, Akul Singhania, Tim Elliott, Marc Tebruegge, Paul Elkington and 3 more

Open access · greenAbstract read
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Host defense mechanisms against Mycobacterium tuberculosis.Cellular and molecular life sciences : CMLS · 2020
    Review
  5. Invariant Natural Killer T-cell Dynamics in Human Immunodeficiency Virus-associated Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  6. Review
  7. Review
  8. Article
  9. LatentFrontiers in immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Andrew ChancellorAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Andrew WhitePublic Health England, National Infections Service, Porton Down, Salisbury, United Kingdom.
Anna S TochevaAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Joe R FennAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Mike DennisPublic Health England, National Infections Service, Porton Down, Salisbury, United Kingdom.
Liku TezeraAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Akul SinghaniaAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Tim ElliottInstitute for Life Sciences, University of Southampton, Southampton, United Kingdom; Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Marc TebrueggeAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom; Global Health Research Institute, University of Southampton, Southampton, United Kingdom; NIHR Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Paul ElkingtonAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom; Global Health Research Institute, University of Southampton, Southampton, United Kingdom; NIHR Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Stephan GadolaAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom; F.Hoffmann-La Roche Ltd, Basel, Switzerland.
Sally SharpePublic Health England, National Infections Service, Porton Down, Salisbury, United Kingdom.
Salah MansourAcademic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; Institute for Life Sciences, University of Southampton, Southampton, United Kingdom. Electronic address: s.mansour@soton.ac.uk.
University Hospital Southampton NHS Foundation Trust · GBPublic Health England · GBUniversity of Southampton · GB

Funding

Cancer Research UK 16997Cancer Research UK A23562Department of Health
6 · The paper itself

Abstract

Correlates of immune protection that reliably predict vaccine efficacy against Mycobacterium tuberculosis (Mtb) infection are urgently needed. Invariant NKT cells (iNKTs) are CD1d-dependent innate T cells that augment host antimicrobial immunity through production of cytokines, including interferon (IFN)-γ and tumour necrosis factor (TNF)-α. We determined peripheral blood iNKT numbers, their proliferative responses and iNKT subset proportions after in vitro antigen expansion by α-galactosylceramide (αGC) in a large cohort of mycobacteria-naïve non-human primates, and macaques from Bacillus Calmette-Guerin (BCG) vaccine and Mtb challenge studies. Animals studied included four genetically distinct groups of macaques within cynomolgus and rhesus species that differ in their susceptibility to Mtb infection. We demonstrate significant differences in ex vivo iNKT frequency between groups, which trends towards an association with susceptibility to Mtb, but no significant difference in overall iNKT proliferative responses. Susceptible animals exhibited a skewed CD4

Indexed as

AnimalsAntigens, CD1dBCG VaccineCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationCells, CulturedCytokinesDisease Models, AnimalGalactosylceramidesGenetic Predisposition to DiseaseHost-Pathogen InteractionsLungLymphocyte ActivationMacaca fascicularisMacaca mulattaalpha-galactosylceramideAntigens, CD1dBCG VaccineCytokinesGalactosylceramidesCD1dCorrelates of protectioniNKTMacaqueTuberculosis

Identifiers

PMID28610792
PMCPMC6168056
OpenAlexW2609463225

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.